Literature DB >> 20625082

Intermittent hypoxia increases arterial blood pressure in humans through a Renin-Angiotensin system-dependent mechanism.

Glen E Foster1, Patrick J Hanly, Sofia B Ahmed, Andrew E Beaudin, Vincent Pialoux, Marc J Poulin.   

Abstract

Intermittent hypoxia (IH) is believed to contribute to the pathogenesis of hypertension in obstructive sleep apnea through mechanisms that include activation of the renin-angiotensin system. The objective of this study was to assess the role of the type I angiotensin II receptor in mediating an increase in arterial pressure associated with a single 6-hour IH exposure. Using a double-blind, placebo-controlled, randomized, crossover study design, we exposed 9 healthy male subjects to sham IH, IH with placebo medication, and IH with the type I angiotensin II receptor antagonist losartan. We measured blood pressure, cerebral blood flow, and ventilation at baseline and after exposure to 6 hours of IH. An acute isocapnic hypoxia experimental protocol was conducted immediately before and after exposure to IH. IH with placebo increased resting mean arterial pressure by 7.9+/-1.6 mm Hg, but mean arterial pressure did not increase with sham IH (1.9+/-1.5 mm Hg) or with losartan IH (-0.2+/-2.4 mm Hg; P<0.05). Exposure to IH prevented the diurnal decrease in the cerebral blood flow response to hypoxia, independently of the renin-angiotensin system. Finally, in contrast to other models of IH, the acute hypoxic ventilatory response did not change throughout the protocol. IH increases arterial blood pressure through activation of the type I angiotensin II receptor, without a demonstrable impact on the cerebrovascular or ventilatory response to acute hypoxia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20625082     DOI: 10.1161/HYPERTENSIONAHA.110.152108

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  51 in total

1.  Losartan abolishes oxidative stress induced by intermittent hypoxia in humans.

Authors:  Vincent Pialoux; Glen E Foster; Sofia B Ahmed; Andrew E Beaudin; Patrick J Hanly; Marc J Poulin
Journal:  J Physiol       Date:  2011-09-19       Impact factor: 5.182

2.  Effect of AT1 receptor blockade on intermittent hypoxia-induced endothelial dysfunction.

Authors:  Noah J Marcus; Nathan R Philippi; Cynthia E Bird; Yu-Long Li; Harold D Schultz; Barbara J Morgan
Journal:  Respir Physiol Neurobiol       Date:  2012-06-21       Impact factor: 1.931

Review 3.  Supine fluid redistribution: should we consider this as an important risk factor for obstructive sleep apnea?

Authors:  Aibek E Mirrakhimov
Journal:  Sleep Breath       Date:  2012-08-08       Impact factor: 2.816

4.  Could Adjunctive Pharmacology Mitigate Cardiovascular Consequences of Obstructive Sleep Apnea?

Authors:  Najib T Ayas; Glen E Foster; Neomi Shah; John Floras; Ismail Laher
Journal:  Am J Respir Crit Care Med       Date:  2019-09-01       Impact factor: 21.405

Review 5.  Intermittent hypoxemia and OSA: implications for comorbidities.

Authors:  Naresh A Dewan; F Javier Nieto; Virend K Somers
Journal:  Chest       Date:  2015-01       Impact factor: 9.410

6.  Reduced arterial vasodilatation in response to hypoxia impairs cerebral and peripheral oxygen delivery in hypertensive men.

Authors:  Igor A Fernandes; Marcos P Rocha; Monique O Campos; João D Mattos; Daniel E Mansur; Helena N M Rocha; Paulo A C Terra; Vinícius P Garcia; Natália G Rocha; Niels H Secher; Antonio C L Nóbrega
Journal:  J Physiol       Date:  2018-02-28       Impact factor: 5.182

7.  Sleep Characteristics in Early Stages of Chronic Kidney Disease in the HypnoLaus Cohort.

Authors:  Adam Ogna; Valentina Forni Ogna; José Haba Rubio; Nadia Tobback; Dana Andries; Martin Preisig; Mehdi Tafti; Peter Vollenweider; Gerard Waeber; Pedro Marques-Vidal; Raphaël Heinzer
Journal:  Sleep       Date:  2016-04-01       Impact factor: 5.849

Review 8.  Therapeutic potential of intermittent hypoxia: a matter of dose.

Authors:  Angela Navarrete-Opazo; Gordon S Mitchell
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-09-17       Impact factor: 3.619

Review 9.  Quintessential risk factors: their role in promoting cognitive dysfunction and Alzheimer's disease.

Authors:  Mak Adam Daulatzai
Journal:  Neurochem Res       Date:  2012-08-12       Impact factor: 3.996

10.  Longitudinal Effect of CPAP on BP in Resistant and Nonresistant Hypertension in a Large Clinic-Based Cohort.

Authors:  Harneet K Walia; Sandra D Griffith; Nancy Foldvary-Schaefer; George Thomas; Emmanuel L Bravo; Douglas E Moul; Reena Mehra
Journal:  Chest       Date:  2016-01-08       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.